Back to search

Article

Three-month treatment with monoclonal antibodies targeting the CGRP pathway is associated with multi-domain improvement of sensory processing and cortical network efficiency: results from a prospective case-control study

2025-05-25

Abstract excerpt

<h4>Abstract Background/Hypothesis</h4> Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP mAbs) are effective drugs for migraine prevention. Worsening of symptoms following their discontinuation challenges their consideration as disease-modifying migraine drugs (DMMD). This study investigates whether changes in sensory processing and cortical network efficiency under CGRP mAb treatment. <h4>Met...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
012edc17-80db-5b1d-8e56-9a1d6aeef8eb
DOI
10.1101/2025.05.24.25328294
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Three-month treatment with monoclonal antibodies targeting the CGRP pathway is associated with multi-domain improvement of sensory processing and cortical network efficiency: results from a prospective case-control studyDOI 10.1101/2025.05.24.25328294
Preventive Treatment With CGRP Monoclonal Antibodies Restores Brain Stem Habituation Deficits and Excitability to Painful Stimuli in Migraineurs: Results From a Prospective Case-control StudySemantic proximity
Safety efficacy and tolerability of the calcitonin gene-related peptide monoclonal antibodies for migraine prevention in a real world settingSemantic proximity
Atogepant modulates brain connectivity in episodic migraine: a longitudinal cohort fMRI studySemantic proximity
Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – An updated systematic review and meta-analysisSemantic proximity
Pathogenesis and Preventive Pharmacotherapy of Migraine Aura: A Critical Review of Cortical Spreading Depolarization Mechanisms, Drug Repurposing Evidence, and the Emerging Therapeutic PipelineSemantic proximity
Cgrp Monoclonal Antibodies: Key Lessons from Real World EvidenceSemantic proximity
Early Improvement of Affective, Fatigue and Allodynic Symptoms in a Cohort of Resistant Migraineurs Treated with Anti-CGRP/R AntibodiesSemantic proximity
Monoclonal Antibodies Against Calcitonin Gene-related Peptide for Migraine Prophylaxis: A Systematic Review of Real-world DataSemantic proximity
Comparative Efficacy and Safety of Calcitonin Gene-Related Peptide Monoclonal Antibodies Versus Oral Gepants for Episodic Migraine Prevention: A Bayesian Network Meta-Analysis of Randomized Controlled TrialsSemantic proximity
Efficacy and Safety of CGRP Monoclonal Antibodies for the Prevention of Migraine Compared with Placebo: A Systematic Review and Meta-AnalysisSemantic proximity
Discontinuing Monoclonal Antibodies Targeting CGRP Pathway After One-Year Treatment: An Observational Longitudinal Cohort StudySemantic proximity
Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biologySemantic proximity
Select a neighboring publication to make it the new centre.